Modular Medical (MODD)
Market Price (8/16/2026): $2.4 | Market Cap: $13.1 MilSector: Health Care | Industry: Life Sciences Tools & Services
Modular Medical (MODD)
Market Price (8/16/2026): $2.4Market Cap: $13.1 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Wearable Health Devices, Show more. | Weak multi-year price returns2Y Excs Rtn is -140%, 3Y Excs Rtn is -166% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -27 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -211% High stock price volatilityVol 12M is 3387% Key risksMODD key risks include [1] potential delays in FDA clearance for its Pivot insulin pump, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Wearable Health Devices, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -140%, 3Y Excs Rtn is -166% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -27 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -211% |
| High stock price volatilityVol 12M is 3387% |
| Key risksMODD key risks include [1] potential delays in FDA clearance for its Pivot insulin pump, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Modular Medical (MODD) stock has lost about 45% since 4/30/2026 because of the following key factors:
1. Significant liquidity concerns and ongoing net losses. Modular Medical reported a net loss of $(6.49M) for fiscal Q1 2027, which ended on June 30, 2026. Diluted loss per share for the quarter was $(1.19). Cash and cash equivalents dramatically decreased to $3.92M at June 30, 2026, from $6.94M at March 31, 2026, leading the company to flag liquidity as a "going-concern risk". The company remains pre-revenue while investing heavily in commercialization.
2. Shareholder dilution from capital raises to fund commercialization. To finance its commercial scale-up, Modular Medical raised approximately $3.0 million through a registered direct offering in April 2026, an additional $0.7 million from at-the-market (ATM) sales in June 2026, and a further $5.1 million under the ATM program after fiscal Q1 2027 ended. While essential for operations, these capital raises likely contributed to investor concerns regarding dilution.
Show more
Modular Medical (MODD) stock has lost about 45% since 4/30/2026 because of the following key factors:
1. Significant liquidity concerns and ongoing net losses. Modular Medical reported a net loss of $(6.49M) for fiscal Q1 2027, which ended on June 30, 2026. Diluted loss per share for the quarter was $(1.19). Cash and cash equivalents dramatically decreased to $3.92M at June 30, 2026, from $6.94M at March 31, 2026, leading the company to flag liquidity as a "going-concern risk". The company remains pre-revenue while investing heavily in commercialization.
2. Shareholder dilution from capital raises to fund commercialization. To finance its commercial scale-up, Modular Medical raised approximately $3.0 million through a registered direct offering in April 2026, an additional $0.7 million from at-the-market (ATM) sales in June 2026, and a further $5.1 million under the ATM program after fiscal Q1 2027 ended. While essential for operations, these capital raises likely contributed to investor concerns regarding dilution.
3. Negative analyst sentiment and bearish technical indicators. As of August 2026, the consensus rating from Wall Street analysts for Modular Medical is "Sell". Technical analysis, updated through August 13, 2026, indicates "sell signals" from both short and long-term Moving Averages, forecasting a potential further decline of 44.90% over the subsequent three months.
Show less
Stock Movement Drivers
Fundamental Drivers
The -42.6% change in MODD stock from 4/30/2026 to 8/15/2026 was primarily driven by a -59.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302026 | 8152026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.34 | 2.49 | -42.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 5 | -59.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 8/15/2026| Return | Correlation | |
|---|---|---|
| MODD | -42.6% | |
| Market (SPY) | 8.0% | 24.0% |
| Sector (XLV) | 14.6% | -5.5% |
Fundamental Drivers
The -81.6% change in MODD stock from 1/31/2026 to 8/15/2026 was primarily driven by a -66.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 8152026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.53 | 2.49 | -81.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 5 | -66.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 8/15/2026| Return | Correlation | |
|---|---|---|
| MODD | -81.6% | |
| Market (SPY) | 12.5% | 28.1% |
| Sector (XLV) | 8.6% | 15.4% |
Fundamental Drivers
The -88.5% change in MODD stock from 7/31/2025 to 8/15/2026 was primarily driven by a -74.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 8152026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.57 | 2.49 | -88.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 5 | -74.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 8/15/2026| Return | Correlation | |
|---|---|---|
| MODD | -88.5% | |
| Market (SPY) | 23.9% | 22.3% |
| Sector (XLV) | 30.0% | 11.6% |
Fundamental Drivers
The -91.5% change in MODD stock from 7/31/2023 to 8/15/2026 was primarily driven by a -92.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8152026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.40 | 2.49 | -91.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 5 | -92.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2023 to 8/15/2026| Return | Correlation | |
|---|---|---|
| MODD | -91.5% | |
| Market (SPY) | 75.6% | 11.3% |
| Sector (XLV) | 30.6% | 7.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MODD Return | 0% | 733% | -9% | -25% | -73% | -83% | -74% |
| Peers Return | 17% | -25% | -19% | 14% | -11% | -26% | -46% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 14% | 108% |
Monthly Win Rates [3] | |||||||
| MODD Win Rate | 0% | 58% | 67% | 33% | 17% | 25% | |
| Peers Win Rate | 56% | 49% | 40% | 50% | 40% | 41% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MODD Max Drawdown | 0% | -64% | -72% | -47% | -78% | -99% | |
| Peers Max Drawdown | -26% | -47% | -53% | -34% | -40% | -54% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PODD, TNDM, MDT, EMBC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/14/2026 (YTD)
How Low Can It Go
| Event | MODD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -32.8% | -18.8% |
| % Gain to Breakeven | 48.8% | 23.1% |
| Time to Breakeven | 17 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -14.9% | -9.5% |
| % Gain to Breakeven | 17.4% | 10.5% |
| Time to Breakeven | 7 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -59.3% | -6.7% |
| % Gain to Breakeven | 145.9% | 7.1% |
| Time to Breakeven | 231 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -23.2% | -24.5% |
| % Gain to Breakeven | 30.2% | 32.4% |
| Time to Breakeven | 8 days | 427 days |
In The Past
Modular Medical's stock fell -32.8% during the 2025 US Tariff Shock. Such a loss loss requires a 48.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MODD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -32.8% | -18.8% |
| % Gain to Breakeven | 48.8% | 23.1% |
| Time to Breakeven | 17 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -59.3% | -6.7% |
| % Gain to Breakeven | 145.9% | 7.1% |
| Time to Breakeven | 231 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -23.2% | -24.5% |
| % Gain to Breakeven | 30.2% | 32.4% |
| Time to Breakeven | 8 days | 427 days |
In The Past
Modular Medical's stock fell -32.8% during the 2025 US Tariff Shock. Such a loss loss requires a 48.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Modular Medical (MODD)
Modular Medical, Inc. (MODD) is a development-stage medical device company dedicated to creating innovative solutions for the diabetes marketplace. The company's primary focus lies in the design, development, and future commercialization of advanced insulin pumps.
These insulin pumps are being developed with proprietary technology specifically engineered to enhance their adoption among patients with diabetes. The core aim is to make insulin pump therapy more accessible, user-friendly, and effective, ultimately increasing its prevalence and improving patient outcomes in managing their condition.
Modular Medical targets the broad market of individuals living with diabetes who require insulin therapy and could benefit from advanced pump technology. By prioritizing enhanced adoption through innovative design, the company aims to serve a wide range of diabetes patients seeking more convenient and efficient methods for insulin delivery.
AI Analysis | Feedback
Here are 1-3 brief analogies for Modular Medical (MODD):
- A development-stage competitor to Insulet (Omnipod) in the insulin pump market.
- An innovative startup aiming to revolutionize insulin pumps, similar to an early Tandem Diabetes Care.
AI Analysis | Feedback
- Insulin Pumps: Medical devices under development designed to deliver insulin to individuals with diabetes, leveraging technology to enhance pump adoption.
AI Analysis | Feedback
Modular Medical, Inc. (MODD) is a development stage medical device company focused on the design, development, and commercialization of insulin pumps. As a development stage company, it has not yet achieved significant commercial sales and, therefore, does not currently have major customers or generate significant product revenue.
However, upon successful commercialization, Modular Medical's insulin pumps are designed for individuals requiring insulin therapy. Consequently, the primary categories of customers it will serve are expected to be:
- Individuals with Type 1 Diabetes: Patients who require continuous and precise insulin delivery due to the body's inability to produce insulin.
- Individuals with Insulin-Dependent Type 2 Diabetes: Patients whose Type 2 diabetes has progressed to a stage requiring insulin therapy and who could benefit from the enhanced glycemic management and flexibility offered by an insulin pump.
AI Analysis | Feedback
AI Analysis | Feedback
James (Jeb) Besser, Chief Executive Officer
James (Jeb) Besser is the Chief Executive Officer of Modular Medical. He has been a Managing Member of Manchester Management LLC for 23 years, which is the largest shareholder of Modular Medical, Inc.. Mr. Besser, a hedge fund manager by trade, also serves as the Portfolio Manager for Manchester Management. He became CEO in February 2022, two weeks after the company uplisted to NASDAQ. Manchester Management has led every financing round into Modular Medical for four years. His compensation is primarily equity-based, as he earns a salary of one dollar per year.
Paul DiPerna, Founder + President
Paul DiPerna is the Founder and President of Modular Medical. He brings 30 years of experience in the medical device industry as a technologist, business executive, and founder of several successful startups. His background includes key roles at Baxter Healthcare in product design, manufacturing, business development, and technical diligence on acquisitions. Mr. DiPerna founded Tandem Diabetes Care, where he created the technology and served as CEO and board member, leading to its $450 million IPO in 2013. He also co-invented the Ivera Medical blood-borne infection control device technology, which was successfully acquired by 3M in 2015. In 2015, he founded Modular Medical, which initially was self-funded before merging into a financed public shell in 2017. He holds over 70 patents, predominantly in blood separation technologies, micro pumping, and diabetes care systems. Mr. DiPerna previously served as President and CEO of Modular Medical Inc. from 2015 to 2022.
James Sullivan, Interim Chief Financial Officer
James Sullivan serves as the Interim Chief Financial Officer of Modular Medical, where he oversees the finance and administrative functions. He possesses over 30 years of experience in financial management and accounting, with significant public-company experience across hardware, software, and cloud-services businesses. Mr. Sullivan has completed more than 15 financings in his career. He has held CFO positions at MoSys, Inc., Apptera, Inc., and 8x8, Inc.. Prior to these roles, he worked in the assurance practice at PricewaterhouseCoopers LLP in New York and Silicon Valley. He is a certified public accountant and holds a Bachelor of Science in Accounting from New York University's Stern School of Business.
Kevin Schmid, Chief Operating Officer
Kevin Schmid is the Chief Operating Officer at Modular Medical. He is an accomplished executive with over four decades of specialized expertise in drug delivery and diabetes management. Before joining Modular Medical, Mr. Schmid was the Vice President of Operations and Business Development at Insulet Corporation and also served as the Chief Executive Officer at Common Sensing. He played a key role in building Insulet's first two facilities.
AI Analysis | Feedback
Key Business Risks for Modular Medical (MODD)
Modular Medical, Inc. (MODD), a development-stage medical device company focused on innovative insulin pump technology, faces several critical risks as it progresses toward commercialization. 1. **Regulatory Approval and Commercialization:** As a pre-revenue company, Modular Medical's entire business strategy and ability to generate revenue hinge on the successful and timely clearance of its Pivot tubeless insulin delivery system by regulatory bodies such as the U.S. Food and Drug Administration (FDA). The Pivot system is currently not cleared for sale by the FDA, and while the company aims for a Q1 2026 commercial launch, this is contingent on a favorable regulatory review. A delay in, or failure to obtain, regulatory approval would prevent the company from selling its primary product, critically impacting its financial viability and future prospects. 2. **Competition and Market Adoption:** The insulin pump market is characterized by established "giants" like Medtronic, Insulet, and Tandem Diabetes Care. Modular Medical aims to differentiate its MODD1 product by focusing on simplicity, affordability, and ease of use, targeting a broader segment of insulin-dependent individuals, particularly "almost-pumpers" who currently rely on multiple daily injections due to the perceived complexity or cost of existing pumps. Despite this strategy, there remains a significant risk that Modular Medical's products may not achieve substantial market acceptance or effectively compete against larger, more entrenched players with extensive distribution networks, brand recognition, and potentially more integrated or advanced device ecosystems. 3. **Financing and Dilution:** As a development-stage company with no material commercial revenue, Modular Medical is heavily reliant on equity financing and capital markets to fund its ongoing research, development, regulatory processes, and eventual commercialization efforts. The company has recently engaged in public offerings of common stock and warrants, which introduces a significant risk of share dilution for existing shareholders. A continuous need for capital, coupled with potential difficulties in securing adequate funding on favorable terms or excessive dilution from future offerings, could impede the company's ability to execute its business plan and sustain operations until profitability.AI Analysis | Feedback
The rapid advancement and increasing adoption of comprehensive automated insulin delivery (AID) or closed-loop systems by established competitors in the diabetes care market. These systems integrate continuous glucose monitors (CGMs) with insulin pumps and sophisticated algorithms to automate insulin delivery, moving beyond standalone pump functionality towards a more "artificial pancreas" experience. As a development-stage company focused on insulin pumps, Modular Medical's ability to compete and gain adoption could be severely hampered if its technology does not seamlessly integrate into or surpass the advanced, integrated solutions offered by industry leaders.
AI Analysis | Feedback
Modular Medical, Inc. (MODD) operates within the broader insulin pump market, with its primary focus on developing and commercializing innovative insulin pumps, including its MODD1 two-part patch pump and the upcoming tubeless Pivot product.
Modular Medical estimates its addressable market for its specific products, targeting individuals who have not yet adopted insulin pumps due to factors like cost and complexity, to be approximately $3 billion. This market is primarily considered for the U.S. initially, with plans for European expansion.
The overall global and U.S. markets for insulin pumps provide a broader context for Modular Medical's operations:
- The global insulin pump market was valued at approximately USD 7.05 billion in 2025 and is projected to grow to USD 22.45 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 13.41% from 2026 to 2034.
- In 2025, North America held the largest share of the global insulin pump market, accounting for 57.34%. The North American market was valued at USD 4.04 billion in 2025.
- The U.S. insulin pump market alone is projected to reach USD 4.51 billion by 2026 and is expected to grow from USD 2,407.3 million in 2024 to USD 3,943.8 million by 2030, at a CAGR of 8.4% from 2025 to 2030.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Modular Medical (MODD) over the next 2-3 years:
- Commercial Launch and Adoption of the MODD1 Insulin Pump: Modular Medical received FDA 510(k) clearance for its next-generation MODD1 insulin delivery pump. The company anticipates commencing initial shipments of the MODD1 by October 2025, which is a critical step for generating its first significant revenues.
- Introduction and Market Penetration of the Pivot Patch Pump: The company has branded a new-generation patch pump as Pivot, with a 510(k) premarket notification submitted to the FDA in November 2025, and a commercial launch projected for the first quarter of 2026, pending regulatory approval. Modular Medical has also successfully validated its Pivot controller manufacturing line, indicating readiness for high-volume production. This product is designed to be a tubeless, removable 3-milliliter patch pump that targets adult "almost-pumpers" who have avoided traditional pumps due to complexity, cumbersomeness, or cost, thus aiming to expand the overall market for insulin pump therapy.
- International Market Expansion: Modular Medical intends to pursue regulatory clearances in the European Union, the United Kingdom, Canada, and other international markets. The company plans to conduct academic and usability studies outside the U.S. in preparation for a full commercial launch in these regions. The appointment of a Head of International Operations further underscores this global expansion strategy.
- Potential Development and Partnerships for GLP-1 Delivery: Modular Medical is exploring the application of its pump technology for GLP-1 (weight loss/diabetes management) drugs. The company believes this market could be as substantial as its core insulin pump business if successful, and it aims to partner with a drug manufacturer for clearance and marketing in this potential new segment.
AI Analysis | Feedback
Share Issuance
- Modular Medical completed its Initial Public Offering (IPO) in February 2022, raising $15 million by issuing 2,500,000 shares at $6.00 per share.
- In February 2024, the company closed a public offering of 9,090,910 shares of common stock at $1.10 per share, generating approximately $10 million in gross proceeds.
- Modular Medical priced a public offering in March 2026, which is anticipated to generate approximately $12 million in gross proceeds from the sale of common stock and warrants.
Inbound Investments
- In March 2025, Modular Medical completed a private placement that raised approximately $12 million.
- Concurrently with the March 2025 private placement, an additional $0.5 million in capital was raised through a direct private placement with a foreign investor.
Capital Expenditures
- Net property, plant, and equipment increased by approximately $2.84 million from March 2022 to March 2023.
- The company's net property, plant, and equipment further increased by approximately $0.91 million from March 2023 to March 2024, and by $1.11 million from March 2024 to March 2025.
Peer Outperformance in Life Sciences Tools & Services
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 8.0% | 74.9% | 121.6% | CAH 400% · MCK 346% · COR 176% |
| Health Care Services | 20 | 20.1% | 37.0% | 6.5% | HIMS 277% · RDNT 130% · DGX 71% |
| Managed Health Care | 8 | 36.7% | -2.3% | 5.2% | OSCR 167% · HQY 61% · ELV 14% |
| Health Care Facilities | 24 | 9.7% | -2.9% | -15.8% | THC 277% · NHC 240% · ENSG 120% |
| Health Care Equipment | 50 | -0.2% | -10.8% | -19.2% | POCI 10862% · UFPT 415% · GKOS 275% |
| Health Care Supplies | 12 | 39.2% | -12.9% | -26.9% | LNTH 304% · HAE 54% · MMSI 36% |
| Pharmaceuticals | 63 | 3.1% | -5.9% | -30.8% | LQDA 2752% · INDV 1525% · ETON 1288% |
| Health Care Technology | 21 | -21.4% | -53.0% | -71.5% | SPOK 144% · TALK -2% · HSTM -4% |
| Life Sciences Tools & Services ← | 108 | -6.6% | -33.4% | -71.9% | SNWV 1835% · ELMD 259% · MEDP 213% |
| Biotechnology | 365 | 7.1% | -28.4% | -78.4% | BRTX 112850% · DNTH 1698% · CELZ 1643% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 22.72 |
| Mkt Cap | 1.6 |
| Rev LTM | 1,041 |
| Op Inc LTM | 248 |
| FCF LTM | 165 |
| FCF 3Y Avg | 104 |
| CFO LTM | 174 |
| CFO 3Y Avg | 116 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.2% |
| Rev Chg 3Y Avg | 7.7% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | 4.4% |
| Op Inc Chg 3Y Avg | 5.8% |
| Op Mgn LTM | 17.8% |
| Op Mgn 3Y Avg | 17.3% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 16.9% |
| CFO/Rev 3Y Avg | 14.3% |
| FCF/Rev LTM | 11.8% |
| FCF/Rev 3Y Avg | 10.7% |
Segment Financials
Operating Income by Segment| $ Mil | 2016 |
|---|---|
| Design, development and eventual commercialization of innovative insulin pumps using modernized | -0 |
| Total | -0 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Design, development and eventual commercialization of innovative insulin pumps using modernized | -19 | -17 |
| Total | -19 | -17 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Design, development and eventual commercialization of innovative insulin pumps using modernized | 19 | 14 | 7 | 10 | 2 |
| Total | 19 | 14 | 7 | 10 | 2 |
Price Behavior
| Market Price | $2.49 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/25/2009 | |
| Distance from 52W High | -89.1% | |
| 50 Days | 200 Days | |
| DMA Price | $3.60 | $7.98 |
| DMA Trend | down | down |
| Distance from DMA | -30.8% | -68.8% |
| 3M | 1YR | |
| Volatility | 147.4% | 3,400.8% |
| Downside Capture | 445.78 | 803.05 |
| Upside Capture | 219.81 | 389.46 |
| Correlation (SPY) | 31.6% | 22.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.46 | 3.06 | 3.22 | 97.30 | 59.96 | 14.54 |
| Up Beta | 6.52 | 4.59 | 4.38 | 343.36 | 232.74 | 36.91 |
| Down Beta | 3.43 | 0.71 | 1.08 | -0.21 | 0.99 | 0.73 |
| Up Capture | -55% | 127% | 213% | 6790% | 2498% | 685% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 15 | 23 | 48 | 99 | 326 |
| Down Capture | 721% | 405% | 375% | 301% | 199% | 112% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 13 | 26 | 38 | 76 | 151 | 393 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MODD | |
|---|---|---|---|---|
| MODD | -88.7% | 3,387.3% | 0.92 | - |
| Sector ETF (XLV) | 27.3% | 15.5% | 1.36 | 11.9% |
| Equity (SPY) | 21.5% | 12.8% | 1.25 | 22.8% |
| Gold (GLD) | 30.0% | 28.5% | 0.91 | 13.0% |
| Commodities (DBC) | 38.1% | 20.1% | 1.49 | -6.7% |
| Real Estate (VNQ) | 14.4% | 13.9% | 0.73 | 11.2% |
| Bitcoin (BTCUSD) | -49.1% | 42.8% | -1.45 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MODD | |
|---|---|---|---|---|
| MODD | -53.3% | 1,614.0% | 0.43 | - |
| Sector ETF (XLV) | 6.3% | 15.0% | 0.24 | 6.1% |
| Equity (SPY) | 13.4% | 17.2% | 0.60 | 8.4% |
| Gold (GLD) | 19.5% | 18.6% | 0.85 | 9.4% |
| Commodities (DBC) | 9.6% | 19.6% | 0.38 | -2.9% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 4.4% |
| Bitcoin (BTCUSD) | 8.0% | 52.8% | 0.34 | 2.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MODD | |
|---|---|---|---|---|
| MODD | -31.6% | 1,614.0% | 0.43 | - |
| Sector ETF (XLV) | 10.2% | 16.6% | 0.50 | 6.1% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 8.4% |
| Gold (GLD) | 12.0% | 16.2% | 0.60 | 9.4% |
| Commodities (DBC) | 7.7% | 18.0% | 0.34 | -2.9% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 4.4% |
| Bitcoin (BTCUSD) | 59.9% | 66.1% | 1.00 | 2.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 06/29/2026 | 10-K |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 06/20/2025 | 10-K |
| 12/31/2024 | 02/13/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 06/21/2024 | 10-K |
| 12/31/2023 | 02/13/2024 | 10-Q |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 06/26/2023 | 10-K |
| 12/31/2022 | 02/13/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 06/29/2026 | 10-K |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 06/20/2025 | 10-K |
| 12/31/2024 | 02/13/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 06/21/2024 | 10-K |
| 12/31/2023 | 02/13/2024 | 10-Q |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 06/26/2023 | 10-K |
| 12/31/2022 | 02/13/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 06/28/2022 | 10-K |
| 12/31/2021 | 02/14/2022 | 10-Q |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 06/29/2021 | 10-K |
| 12/31/2020 | 02/12/2021 | 10-Q |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/12/2020 | 10-Q |
| 03/31/2020 | 06/29/2020 | 10-K |
| 12/31/2019 | 02/13/2020 | 10-Q |
| 09/30/2019 | 11/14/2019 | 10-Q |
Modular Medical — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.